About MacroGenics
MacroGenics is a company based in Rockville (United States) founded in 2000. It operates as a Professional Services. MacroGenics has raised $126.02 million across 13 funding rounds from investors including Lilly, ARE and NIH. The company has 341 employees. MacroGenics has completed 1 acquisition, including Raven Biotechnologies. MacroGenics offers products and services including Lorigerlimab, MGC026, MGC028, and MGD024. MacroGenics operates in a competitive market with competitors including argenx, Alexion, Zai Lab, Kodiak Sciences and BigHat, among others.
- Headquarter Rockville, United States
- Employees 341
- Stage Public
- SectorsHealthcare
- Phone•••• ••••
- Website macrogenics.com
- Social LinkedIn X
- Legal Name Macrogenics, Inc.
- Annual Revenue$149.5 M (USD)-0.31as on Dec 31, 2025
- Net Profit-$74.62 M (USD)-11.43as on Dec 31, 2025
- EBITDA-$65.67 M (USD)36.27as on Dec 31, 2025
- Total Equity Funding$126.02M (USD)
in 13 rounds
- InvestorsLilly
& 22 more
- Employee Count341
- Investments & Acquisitions
Products & Services of MacroGenics
MacroGenics offers a comprehensive portfolio of products and services, including Lorigerlimab, MGC026, MGC028, and MGD024.
Innovative antibody therapy targeting PD-1 and CTLA-4 proteins.
Antibody-drug conjugate targeting B7-H3 for cancer treatment.
Antibody-drug conjugate targeting ADAM9 for cancer therapy.
Bispecific antibody targeting CD123 and CD3 molecules.
Funding Insights of MacroGenics
MacroGenics has successfully raised a total of $126.02M across 13 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $126.02M
- Total Rounds 13
- First Round $13.5M
(Sep 2001)
- Investors Count 23
Latest 10 of 13 funding rounds of MacroGenics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2019 | – | Post-IPO | – | – | |
| Jan 2011 | $12.02M | Series D | – | – | – |
| Jul 2010 | $9.8M | Grant | – | – | |
| Jun 2010 | $4.66M | Grant | – | – | |
| Jun 2010 | $3M | Grant | – | – | |
| Jun 2010 | $3M | Grant | – | – | |
| Aug 2009 | $3.82M | Grant | – | – | |
| Sep 2008 | $25M | Series D | – | Nextech Venture | |
| Jun 2008 | $3.82M | Grant | – | – | |
| Jul 2006 | $3.82M | Grant | – | – |
23 investors in total: 23 institutional.
Investors in MacroGenics
MacroGenics has secured backing from 23 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, ARE and NIH.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
PE firm investing in Asia and Europe | 1993 | bbbiotech.ch | Schaffhausen, Switzerland | |
- | – | nextechventure.com | - | |
Arcus Ventures is focused on investing in oncology companies. | – | arcusventures.com | New York, United States | |
Venture capital firm focused on healthcare companies | – | altapartners.com | Jackson, United States | |
CID Capital is engaged in lower-middle-market buyout investments. | 1981 | cidcap.com | Carmel, United States | |
Early-stage investing in IT and healthcare ventures. | – | interwest.com | - | |
Venture capital is invested in AI, energy, and various sectors. | – | mucap.co.jp | Tokyo, Japan | |
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Venture capital firm investing in life sciences companies | – | redabbey.com | Baltimore, United States | |
- | – | rivervest.com | - |
Investor details for MacroGenics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of MacroGenics
118 people are tracked at MacroGenics (61 in leadership, 9 in board & advisors, 48 in team); the tracked headcount is 341.
| Name | Role | Group |
|---|---|---|
Monirath Hav (MD, PhD) | Director, Translational Pathology | Leadership |
Scott Koenig | President & CEO | Leadership |
Kristina Western (Fox) | Associate Outsourcing & Budget Director | Leadership |
Xiaoyan Zhang | Executive Director, Clinical Pharmacology/clinical Development | Leadership |
Lynn Cilinski | Vice President, Controller and Treasurer | Leadership |
Matt Stephens | Associate Director, Clinical Outsourcing & Budgeting | Leadership |
Katherine Kopeikina | Associate Intellectual Property Director | Leadership |
Melanie Y. | Associate Director, Clinical Lab Operations | Leadership |
Janine Koucheki | Associate Director Clinical Operations | Leadership |
Ramona Dougherty | Associate Director Quality Assurance Operations | Leadership |
Denise Moak | Associate Director, Clinical Systems | Leadership |
Stephen Eck | Senior Vice President, Clinical Development & Chief Medical Officer | Leadership |
Ezio Bonvini | Senior Vice President, Research and Chief Scientific Officer | Leadership |
James Karrels | Senior Vice President, Chief Financial Officer and Secretary | Leadership |
Eric Risser | COO | Leadership |
Susan Brann | Associate Director, Clinical Operations | Leadership |
Nikita Gagrat | Director, Key Accounts Oncology - Market Access & GPO | Leadership |
Steve Harig | Senior Vice President Human Resources | Leadership |
Shannon Schreiner | Director, IT Infrastructure And Operations | Leadership |
Jacin Hayes | Associate Director, Manufacturing Outsourcing | Leadership |
98 more people are available in the full profile.
Complete people profiles for MacroGenics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of MacroGenics
MacroGenics is a publicly listed company on the NASDAQ with ticker symbol MGNX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date10 Oct 2013
- Listed onNASDAQ: MGNX
- Listed entityMacroGenics, Inc.
- Exchange sectorHealth technology
- ISINUS5560991094
- Share price$3.55 · 2026-10-08
- Market capitalisation$226.1M
- EPS (diluted, trailing year)$-0.23
- Volume (last session)768,068
Financials of MacroGenics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $149.5M | -$74.6M | -$65.7M |
| 2024 | $150.0M | -$67.0M | -$103.0M |
| 2023 | $58.8M | -$9.1M | -$158.6M |
| 2022 | $151.9M | -$119.8M | -$109.5M |
| 2021 | $77.5M | -$202.1M | -$191.5M |
Detailed financial statements for MacroGenics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by MacroGenics
MacroGenics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Raven Biotechnologies.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Monoclonal antibodies targeting cell surfaces for cancer therapies are developed. | ravenbio.com | San Francisco, United States | 1998 | Jul 2008 | •••• |
Complete acquisition details for MacroGenics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of MacroGenics
5 dated milestones of MacroGenics across 19 years, from founding to its latest funding, stage changes and deals.
- Founded MacroGenics is founded.
- Funding First funding round of $13.5M.
- Acquisition Acquires Raven Biotechnologies.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO,.
Competitors of MacroGenics
MacroGenics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as argenx, Alexion, Zai Lab, Kodiak Sciences and BigHat, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| argenx.com | 2008 | Ghent, Belgium | $61.9M | 355 | Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | |
| alexion.com | 1992 | Zurich, Switzerland | $8M | 1 | Therapies for rare and devastating diseases are developed by Alexion. | |
| zailaboratory.com | 2013 | Shanghai, China | $160M | – | Antibody-based therapies for cancers and inflammatory diseases are developed. | |
| kodiak.com | 2009 | Palo Alto, United States | $35.84M | 112 | Therapeutics for retinal diseases are developed by the company. | |
| bighatbio.com | 2019 | San Carlos, United States | $148.41M | – | Antibody therapies are developed through machine learning and synthetic biology. | |
| scholarrock.com | 2012 | Cambridge, United States | $103.3M | 150 | Antibody-based drugs for primary myopathies are developed and targeted. | |
| visterrainc.com | 2007 | Cambridge, United States | $116.17M | 79 | Developer of monoclonal antibodies against infectious diseases | |
| iggenix.com | 2019 | San Francisco, United States | $75M | – | Therapeutic solutions for food allergies are developed via antibody platforms. |
Detailed competitors of MacroGenics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of MacroGenics
The website of MacroGenics (macrogenics.com) receives about 10.4K visits a month.
- Monthly visits10.4K
▼ 21.4% vs previous month
Websites whose visitors overlap most with MacroGenics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| oncomed.com | 100% | – | – | View details | |
| xencor.com | 98% | 22.2K | #2,563,685 | View details | |
| immunomix.com | 94% | 2.7K | #5,105,289 | View details | |
| americangene.com | 93% | 16.6K | #1,411,276 | View details | |
| senseibio.com | 91% | 4.5K | #4,696,262 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 21 similar websites and full traffic analytics for MacroGenics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 21 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Macrogenics
Complete news archive for MacroGenics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to MacroGenics
10 companies that operate in the same segment as MacroGenics (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about MacroGenics
MacroGenics was founded in 2000 and raised its 1st funding round 1 year after it was founded.
MacroGenics is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.
MacroGenics is a funded company, having raised a total of $126.02M across 13 funding rounds to date. The company's 1st funding round was a Grant of $3.82M, raised on Sep 2001.
MacroGenics has 341 employees.
Annual revenue of MacroGenics is $149.5M as on Dec 31, 2025.
MacroGenics, Inc. is engaged in the development and commercialization of innovative monoclonal antibody-based therapeutics for cancer treatment. The company operates within the biopharmaceutical sector, focusing on unmet medical needs through a broad pipeline of investigational product candidates. Solutions are developed using advanced antibody-based technologies and fully-integrated development capabilities, including GMP manufacturing. Efforts are directed towards creating breakthrough biologics aimed at transforming patient outcomes in oncology.
MacroGenics's top competitors include argenx, Zai Lab and Kodiak Sciences.
MacroGenics offers Lorigerlimab, MGC026, MGC028, and MGD024.
Yes, MacroGenics is publicly traded on NASDAQ under the ticker symbol MGNX.
MacroGenics has made 1 acquisition, including Raven Biotechnologies.
MacroGenics operates through Macrogenics, Inc..